Press release
Acute Pain Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
Explore our latest breakthroughs in Acute Pain Research. Learn more about our innovative pipeline today! @ Acute Pain Pipeline Outlook [https://www.delveinsight.com/sample-request/acute-pain-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Acute Pain Pipeline Report
* In April 2025, Vertex Pharmaceuticals Incorporated announced a study is to evaluate the efficacy, safety, tolerability and pharmacokinetics of VX-993 in treating acute pain after a bunionectomy.
* In April 2025, Latigo Biotherapeutics conducted a phase 2 dose-ranging study Evaluating the Efficacy and Safety of LTG 001 for Acute Pain After Surgical Removal of Impacted Third Molars.
* DelveInsight's Acute Pain Pipeline report depicts a robust space with 25+ active players working to develop 25+ pipeline therapies for Acute Pain treatment.
* The leading Acute Pain Companies such as Neumentum, CGeneTech, Algomedix, TREMEAU PHARMACEUTICALS, Vertex Pharmaceuticals, Kures, Inc., Jiangsu Hengrui Medicine Co., SiteOne Therapeutics, Mylan Specialty, LP, Viatris Inc., Tetra Bio-Pharma, and Scilex Pharmaceuticals, Inc . and others.
* Promising Acute Pain Pipeline Therapies such as Methoxyflurane 3mL, Methoxyflurane, S-Ibuprofen, VX-993, HB/APAP, Cebranopadol, Oxycodone IR, Suzetrigine, VX-548, PF614 and others.
Stay informed about the cutting-edge advancements in Acute Pain treatments. Download for updates and be a part of the revolution in neurology care @ Acute Pain Clinical Trials Assessment [https://www.delveinsight.com/sample-request/acute-pain-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Acute Pain Emerging Drugs Profile
* NTM-001: Neumentum
NTM-001 is Neumentum's lead product candidate: a novel, alcohol-free formulation of the powerful NSAID ketorolac, in a pre-mixed bag designed for 24-hours of continuous infusion following surgery. It is being evaluated to manage moderately severe acute pain that requires analgesia at the opioid-level, usually in a postoperative setting.
* CGT 1507: CGeneTech
Otenaproxesul is a novel nonsteroidal anti-inflammatory drug ("NSAID") that releases hydrogen sulfide. Antibe is leveraging the drug's remarkable potency, gastrointestinal ("GI") protection and overall safety profile for use in acute pain indications. Otenaproxesul, is being developed as a safer non-opioid analgesic for post-operative pain.
* TRPA1 Antagonist: Algomedix
Algomedix is developing a non-opioid, non-addictive, novel TRPA1 antagonist for the treatment of acute and chronic pain. Algomedix is focused on the advancement of a novel, small molecule TRPA1 antagonist for the treatment of pain. This clinical candidate offers the potential for a next-generation analgesic devoid of the addiction and abuse liabilities, as well as other adverse effects inherent in the opioid class of drugs.
Acute Pain Market Drivers
* Increasing demand for long-term pain management among the geriatric population
* Government investments for healthcare interoperability
Acute Pain Market Barriers
* The availability of alternate pain management systems
* Side-effects associated with the disease
Learn more about Acute Pain Drugs Opportunities in our groundbreaking Acute Pain Research and development projects @ Acute Pain Unmet Needs [https://www.delveinsight.com/sample-request/acute-pain-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
The Acute Pain pipeline report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Acute Pain with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Acute Pain Treatment.
* Acute Pain Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Acute Pain Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Acute Pain market.
Acute Pain Companies
Neumentum, CGeneTech, Algomedix, TREMEAU PHARMACEUTICALS, Vertex Pharmaceuticals, Kures, Inc., Jiangsu Hengrui Medicine Co., SiteOne Therapeutics, Mylan Specialty, LP, Viatris Inc., Tetra Bio-Pharma, and Scilex Pharmaceuticals, Inc . and others
Acute Pain pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Intra-articular
* Intraocular
* Intrathecal
* Intravenous
* Ophthalmic
* Oral
* Parenteral
* Subcutaneous
* Topical
* Transdermal
Acute Pain Products have been categorized under various Molecule types such as
* Oligonucleotide
* Peptide
* Small molecule
Discover the latest advancements in Acute Pain treatment by visiting our website. Stay informed about how we're transforming the future of neurology @ Acute Pain Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/acute-pain-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Acute Pain Pipeline Report
* Coverage- Global
* Acute Pain Companies- Neumentum, CGeneTech, Algomedix, TREMEAU PHARMACEUTICALS, Vertex Pharmaceuticals, Kures, Inc., Jiangsu Hengrui Medicine Co., SiteOne Therapeutics, Mylan Specialty, LP, Viatris Inc., Tetra Bio-Pharma, and Scilex Pharmaceuticals, Inc. and others.
* Acute Pain Pipeline Therapies- Methoxyflurane 3mL, Methoxyflurane, S-Ibuprofen, VX-993, HB/APAP, Cebranopadol, Oxycodone IR, Suzetrigine, VX-548, PF614 and others.
* Acute Pain Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Acute Pain Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase II
For a detailed overview of our latest research findings and future plans, read the full details of Acute Pain Pipeline on our website @ Acute Pain Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/acute-pain-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Acute Pain: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Acute Pain- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* NTM-001: Neumentum
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Drug name : Company name
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Drug name : Company name
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* TRPA1 Antagonist: Algomedix
* Drug profiles in the detailed report.....
* Inactive Products
* Acute Pain Key Companies
* Acute Pain Key Products
* Acute Pain- Unmet Needs
* Acute Pain- Market Drivers and Barriers
* Acute Pain- Future Perspectives and Conclusion
* Acute Pain Analyst Views
* Acute Pain Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=acute-pain-clinical-trials-and-studies-2025-ema-pdma-fda-approvals-mechanism-of-action-roa-nda-ind-and-companies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/acute-pain-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Acute Pain Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies here
News-ID: 3996178 • Views: …
More Releases from ABNewswire
Smarta Switch Celebrates 10 Years of Helping Devon & Cornwall Businesses Reduce …
Smarta Switch, the Plymouth UK-based business cost-reduction consultancy, is celebrating its 10th anniversary, marking a decade of helping local companies cut their energy bills, improve profit margins, and navigate an increasingly complex utilities market. In 2025 alone it helped businesses save more than 300,000.
Founded in 2015, Smarta Switch has grown from a small Plymouth start-up into one of the region's most trusted independent brokers for business energy, telecoms, and water…
Austin Bankruptcy Lawyer Breaks Down Chapter 7 VS. 13 For Debt Relief In Texas
Austin Bankruptcy Lawyers explains the key differences between Chapter 7 and Chapter 13 bankruptcy for Texas residents. They aim to help individuals understand eligibility, timelines, and debt relief options while highlighting how legal guidance can support more informed decisions and long-term financial stability.
Austin, TX - Austin Bankruptcy Lawyers [https://www.austinbankruptcylawyers.com/] shares a straightforward comparison of Chapter 7 and Chapter 13 bankruptcy to help Texans choose the option that better fits their…
Divorce Attorney In Arlington VA Explains Property Division In Virginia Divorces
The Irving Law Firm outlines how Virginia courts divide marital property in divorce cases. A divorce attorney in Arlington VA can help couples understand equitable distribution and what may happen to their home, savings, and other assets.
Arlington, VA - An experienced divorce attorney in Arlington, VA [https://www.theirvinglawfirm.com/locations/arlington-va/], from The Irving Law Firm, is shedding light on how property division works under Virginia law. With many couples uncertain about what happens…
Protheragen's FLEXFlash Platform Powers Up Next-Generation Pet Supplement Develo …
Protheragen has launched its pet supplement OEM and ODM services anchored by its proprietary FLEXFlash platform, ushering in a new era of advanced, consumer-centric pet supplements.
As pet owners worldwide become more health-oriented towards their companions, the global pet supplement market is booming - though with some long-standing hurdles: homogenized products, inconvenient feeding procedures, and expensive, complicatedquality-checking. Taking on these challenges, Protheragen, a pioneer in pet health solutions, has launched its…
More Releases for Acute
Acute Lymphoblastic Leukemia Therapeutics Market Size, Acute Lymphoblastic Leuke …
Acute Lymphoblastic Leukemia Therapeutics Market Dynamics are clarified by an in-depth review of facts on current and emerging trends. To understand a resource, the paper uses Porter's five forces to examine the importance of numerous qualities such as understanding of suppliers and customers, dangers provided by various agents, competitive strength, and promising new businesses. precious. Furthermore, the study covers numerous firms' Acute Lymphoblastic Leukemia Therapeutics research data, benefit, gross margin,…
Acute Conjunctivitis Treatment Market: The Future Insights Of Global Acute Conju …
Acute Conjunctivitis Treatment Market
Acute Conjunctivitis Treatment Market, or pink eye, is an irritation or inflammation of the conjunctiva that covers the white part of the eyeball. It can be caused by allergies or a bacterial or viral infection. Acute Conjunctivitis Treatment Market can be highly communicable and can be spread easily by the contact with secretions of eye from the infected person. Conjunctivitis often resolves on its own, but…
Acute Renal Failure (ARF) (Acute Kidney Injury) Global Clinical Trials Review, H …
ReportsWorldwide has announced the addition of a new report title Acute Renal Failure (ARF) (Acute Kidney Injury) Global Clinical Trials Review, H1, 2017 to its growing collection of premium market research reports.
GlobalData's clinical trial report, “Acute Renal Failure (ARF) (Acute Kidney Injury) Global Clinical Trials Review, H1, 2017" provides an overview of Acute Renal Failure (ARF) (Acute Kidney Injury) clinical trials scenario. This report provides top line data relating to…
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical T …
ReportsWorldwide has announced the addition of a new report title Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical Trials Review, H1, 2017 to its growing collection of premium market research reports.
GlobalData's clinical trial report, “Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical Trials Review, H1, 2017" provides an overview of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) clinical trials scenario. This report provides top line data relating to…
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Global Clinical Tri …
ReportsWorldwide has announced the addition of a new report title Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Global Clinical Trials Review, H1, 2017 to its growing collection of premium market research reports.
GlobalData's clinical trial report, “Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Global Clinical Trials Review, H1, 2017" provides an overview of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) clinical trials scenario. This report provides top line data relating to…
H2 2016 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeut …
Albany, New York, January 03, 2017: A recent forecast report focusing on the Acute Myelocytic Leukemia Market has been added to the wide portfolio of Market Research Hub (MRH). It is entitled as, “Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2016” which has been equipped by in-depth market examination with inputs from the industry experts. It covers the current market scenario and also its future growth…
